0.763
-0.02 (-2.08%)
| Previous Close | 0.779 |
| Open | 1.04 |
| Volume | 39,119,721 |
| Avg. Volume (3M) | 845,875 |
| Market Cap | 97,862,280 |
| Price / Sales | 0.440 |
| Price / Book | 0.290 |
| 52 Weeks Range | |
| Earnings Date | 13 Mar 2026 |
| Profit Margin | -15.50% |
| Operating Margin (TTM) | -18.31% |
| Diluted EPS (TTM) | -0.390 |
| Quarterly Revenue Growth (YOY) | 30.80% |
| Total Debt/Equity (MRQ) | 24.95% |
| Current Ratio (MRQ) | 1.35 |
| Operating Cash Flow (TTM) | -8.82 M |
| Levered Free Cash Flow (TTM) | 8.34 M |
| Return on Assets (TTM) | -3.32% |
| Return on Equity (TTM) | -6.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Household & Personal Products (US) | Mixed | Bearish |
| Household & Personal Products (Global) | Mixed | Bearish | |
| Stock | Waldencast plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region. |
|
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Investment Style | Small Value |
| % Held by Insiders | 56.95% |
| % Held by Institutions | 25.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Zeno Equity Partners Llp | 31 Dec 2025 | 12,252,580 |
| Milestones Administradora De Recursos Ltda. | 31 Dec 2025 | 2,425,677 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™ |
| 05 Feb 2026 | Announcement | Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™ |
| 03 Feb 2026 | Announcement | Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |